This week Dr. Bruno Paiva, our co-scientific director, presented a review on the study of minimal residual disease at the issue 17 edition of the International Myeloma Workshop in Boston. This is a meeting that is dedicated to fostering scientific and clinical exchange on the latest advances in multiple myeloma and related plasma cell disorders. This edition was attended by more than 3,000 participants from various countries who covered several topics related to the topic, including immunotherapeutic approaches and innovative results from early and large randomized clinical trials. In addition, two papers conducted in our laboratories were presented in the prestigious "Late-breaking abstracts" session. 

The abstracts presented by researchers from group are entitled: "Characterization of the immune microenvironment identifies CD27 negative T cells as potential source reactive lymphocytes in myeloma" and "Circulating tumor cells for non-invasive Genetics characterization of multiple myeloma". These works may have an impact B on treatments, as they point out a new approach to monitor the immune response, as well as the possibility of performing genetic programs of study on tumor cells isolated from peripheral blood, without the need for invasive and painful methods such as bone marrow aspirates.